Paroxysmal supraventricular tachycardia
Conditions
Interventions
Intervention Group:Pulsed field ablation (PFA)
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years (inclusive), male or female; 2. Patients diagnosed with paroxysmal supraventricular tachycardia (including atrioventricular reentrant tachycardia, atrioventricular nodal reentrant tachycardia, and Wolff-Parkinson-White syndrome) by surface electrocardiogram, and scheduled to undergo first-time catheter ablation; 3. Willing to participate voluntarily in this study, understand all risks and benefits described in the informed consent document, and sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have previously undergone cardiac catheter ablation; 2. Patients found preoperatively to have other types of arrhythmias (e.g., ventricular arrhythmias, atrial flutter, atrial tachycardia, atrial fibrillation, etc.); 3. Patients with left ventricular ejection fraction (LVEF) < 40%; 4. Patients with known intracardiac thrombus or diagnosed with myxoma; 5. Patients with New York Heart Association (NYHA) functional class III-IV; 6. Patients with significant congenital heart defects (e.g., atrial septal defect or anomalous pulmonary veins, excluding patent foramen ovale); 7. Patients with a prosthetic heart valve; 8. Patients who have undergone aortic valve replacement and require a retrograde arterial approach for ablation; 9. Patients who have undergone atrial septal repair and require a transseptal puncture approach for ablation; 10. Patients with an implanted pacemaker or implantable cardioverter-defibrillator (ICD); 11. Patients with active systemic infection; 12. Patients with significant bleeding tendency or renal failure requiring hemodialysis; 13. Patients with clear contraindications to interventional procedures, judged by the investigator as unable to undergo interventional surgery; 14. Patients who have had a myocardial infarction or any cardiac intervention (excluding coronary angiography) / open-heart surgery within 3 months; 15. Patients who have had a stroke or other serious cerebrovascular disease within 6 months; 16. Patients with malignant tumors or end-stage diseases and an expected survival < 6 months; 17. Patients with severe underlying systemic diseases; 18. Women who are pregnant or breastfeeding; 19. Patients currently participating in other drug or medical device clinical trials, or any interventional clinical study; 20. Patients considered by the investigator to be unsuitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute procedural success rate;6?month freedom from PSVT recurrence; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3?month freedom from PSVT recurrence;Patient satisfaction assessment at 6 months post?procedure;Procedural parameters; | — |
Countries
China
Contacts
Public ContactRui Zeng
West China Hospital of Sichuan University
Outcome results
None listed